News

The Subject Expert Committee (SEC) under the COVID-19 division of the Central Drugs Standard Control Organization (CDSCO) has ...
The Department of Health and Human Services under Robert F. During his Senate confirmation hearings, Health Secretary Robert ...
Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...
Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said the agency’s new risk-based COVID-19 vaccine framework contradicts the ...
Retail investor chatter around vaccine makers Novavax, Moderna, and Pfizer rose on Wednesday, ahead of a closely watched CDC ...
The U.S. FDA approved 14 drugs in May, a decline from 20 in April and 22 in March. That brings the year-to-date total for 2025 to 84 approvals, the second highest on record for this period, just ...
The data showed that both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators ...
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.
Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
Per Novavax, these responses were similar to those seen with its own approved COVID-19 vaccine, Nuvaxovid, and Sanofi’s SNY influenza vaccine, Fluzone HD. High Yield Savings Offers Earn 4.10% ...
The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness ...
May 18 (UPI) --The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.The agency approved the vaccine only for people 65 and older ...